MedTrace Logo

Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.

NCT06159920 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2024-03-06

No results posted yet for this study

Summary

Neuroendocrine tumors (NETs) constitute approximately 0.5% of malignancies. To date, diagnosis at an increasingly early stage of the disease is possible thanks to recent technological advances in biomedical imaging. In particular, the traditional work-up for these pathologies includes endoscopy, magnetic resonance imaging (MRI) and computed tomography (CT). Furthermore, the integrated positron emission tomography methods (PET/CT and PET/MRI) are innovative molecular imaging techniques and represent a continually expanding field of research in the oncology setting. In particular, PET is taking on an increasingly relevant role for the study of neuroendocrine tumors, also thanks to the introduction of increasingly accurate radiopharmaceuticals (targeted towards somatostatin receptors), thus opening the way to new possibilities for the diagnosis andcharacterization of these tumors, is in the staging and restaging phase .

Conditions

Interventions

DIAGNOSTIC_TEST

diagnostic accuracy

The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.

Sponsors & Collaborators

  • IRCCS San Raffaele

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2024-12-27
Completion
2024-12-27

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159920 on ClinicalTrials.gov